Research has shown that during gradual weight loss from lifestyle interventions and older weight loss medications, roughly one-fourth of total weight loss is expected to come from lean mass.3 Popular GLP‑1 medications, such as semaglutide and tirzepatide, typically produce more rapid and substantial weight loss, which is often associated with a higher proportion of lean mass loss.2 One study found that on average, lean mass accounted for around 40% of the weight people lost.4

Omada's 12-week study followed 245 adults with obesity (BMI ≥30), including 151 Omada members and 94 control participants, all of whom had recently started a GLP-1 for weight management.1 It compared a group that was given access to Omada's GLP-1 Care Track–designed as a wraparound program to promote strength training and physical activity with one-on-one support to protect muscle mass and improve overall body composition–to a group that did not receive access to Omada. Both groups used an at-home scale to track weight and body composition and completed surveys to assess emotional health, well-being, self-efficacy, and physical function.

On average, compared with controls, Omada members lost 1.8 times more total weight (6.0% vs. 3.3% of starting weight).1 When assessing body composition, Omada members reduced their body fat percentage by 3.3%, two times more than controls, and increased muscle mass percentage by nearly three times.1 They also reported greater improvements in mental health, physical functioning, and confidence in their ability to lose weight.1 Notably, these results in Omada's GLP-1 Care Track members were seen even though more than a quarter of the comparison group members reported participating in non-Omada wellness programs during the study period.1